CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Comparison of Accuracy of One-Use Methods for Calculating Fractional Flow Reserve by Intravascular Optical Coherence Tomography to That Determined by the Pressure-Wire Method The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial Coronary Microcirculation Downstream Non-Infarct-Related Arteries in the Subacute Phase of Myocardial Infarction: Implications for Physiology-Guided Revascularization Prognostic Implication of Thermodilution Coronary Flow Reserve in Patients Undergoing Fractional Flow Reserve Measurement

Review Article2020 Dec 26;ehaa824.

JOURNAL:Eur Heart J. Article Link

Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey

D Cao, R Chandiramani, M Chiarito et al. Keywords: antithrombotic therapy;

ABSTRACT

Since its introduction in 1977, percutaneous coronary intervention has become one of the most commonly performed therapeutic procedures worldwide. Such widespread diffusion, however, would have not been possible without a concomitant evolution of the pharmacotherapies associated with this intervention. Antithrombotic agents are fundamental throughout the management of patients undergoing coronary stent implantation, starting from the procedure itself to the long-term prevention of cardiovascular events. The last 40 years of interventional cardiology have seen remarkable improvements in both drug therapies and device technologies, which largely reflected a progressive understanding of the pathophysiological mechanisms of coronary artery disease, as well as procedure- and device-related adverse events. The purpose of this article is to provide an overview of the important milestones in antithrombotic pharmacology that have shaped clinical practice of today while also providing insights into knowledge gaps and future directions.